Cormedix (HAM:19KA) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:19KA Cormedix Inc HAM:19KA
46 GF Score
Price €7.30
GF Value €57.94
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix FFO per Share?

FFO per Share only applies to REITs.

HAM:19KA
46GF Score
Cormedix Inc HAM:19KA
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cormedix (HAM:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €7.30 is trading 87.4% below its estimated GF Value™ of €57.94. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for HAM:19KA:

  • FFO per Share:
  • GF Value™: €57.94 vs. price of €7.30 (87.4% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cormedix Business Description

Other Exchanges CRMD:USA19KA:Germany
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
46GF Score

Get the complete analysis for HAM:19KA

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.30
Price
€57.94
GF Value